Zacks Investment Research upgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a sell rating to a hold rating in a research report released on Saturday, January 20th.
According to Zacks, “Post a promising third-quarter 2017 performance we are encouraged by Thermo Fisher’s series of product launches along with progress in precision medicine initiatives. At the same time, we are upbeat about Thermo Fisher recently completing the acquisition of Phenom-World. Moreover, the newly-integrated FEI Company has already started to boost its analytical instruments arm. We are currently looking forward to Thermo Fisher gaining entry into the CDMO market through the recently-closed $7.2 billion acquisition of Patheon. The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through 2017. Unfavorable macroeconomic conditions continue to weigh heavily on Thermo Fisher's stocks. Over the past six months, Thermo Fisher is trading above the broader industry. On the flip side, competitive headwinds and rising operating costs continue to pose a threat on the stock's value.”
Other equities research analysts have also recently issued research reports about the company. Barclays restated an overweight rating and set a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Jefferies Group restated a hold rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Leerink Swann reiterated a buy rating on shares of Thermo Fisher Scientific in a research report on Monday, October 30th. Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a buy rating and a $225.00 price objective for the company. Finally, BTIG Research started coverage on Thermo Fisher Scientific in a research report on Friday, January 5th. They issued a buy rating and a $230.00 price objective for the company. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $220.50.
Thermo Fisher Scientific (NYSE TMO) opened at $204.51 on Friday. Thermo Fisher Scientific has a 52-week low of $151.74 and a 52-week high of $226.44. The company has a market capitalization of $81,580.00, a PE ratio of 36.52, a PEG ratio of 1.47 and a beta of 1.11. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the business earned $2.41 earnings per share. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. research analysts predict that Thermo Fisher Scientific will post 10.81 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date is Wednesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is 10.71%.
In other news, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the transaction, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the transaction, the chief executive officer now owns 302,577 shares in the company, valued at $58,016,113.98. The disclosure for this sale can be found here. Insiders have sold 144,327 shares of company stock worth $28,680,042 over the last quarter. 0.49% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the stock. Amalgamated Bank raised its holdings in shares of Thermo Fisher Scientific by 57.0% during the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after buying an additional 16,308 shares during the period. Mutual of America Capital Management LLC grew its stake in Thermo Fisher Scientific by 2.1% during the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after purchasing an additional 977 shares in the last quarter. Americafirst Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at approximately $876,000. State Board of Administration of Florida Retirement System grew its stake in Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after purchasing an additional 5,213 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at approximately $1,451,000. Institutional investors and hedge funds own 86.11% of the company’s stock.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/thermo-fisher-scientific-tmo-upgraded-by-zacks-investment-research-to-hold.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.